Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06539702
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-09
Brief Title:
Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology
Sponsor:
None
Organization:
None
Study Overview
Official Title:
To Reveal the Predictive Value of Preoperative Hemogram Parameters and BRAF Molecular Test in Predicting Malignancy in Cases With Thyroid Nodules Detected by Bethesda 3 Cytology
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Bethesda3
Brief Summary:
The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology
The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology
Primary outcome Preoperative hemogram parameters Secondary outcome BRAF positivity
The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology
Primary outcome Preoperative hemogram parameters Secondary outcome BRAF positivity
Detailed Description:
The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology
The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology
Primary outcome Preoperative hemogram parameters Secondary outcome BRAF positivity This study aims to reduce unnecessary thyroidectomies thyroidectomy complications and treatment costs due to Bethesda 3 cytology
The age and gender of all patients to be included in the study will be recorded Mean Platelet Volume MPV Neutrophillymphocyte Ratio NLR PlateletLymphocyte Ratio PLR and LymphocyteMonocyte Ratio LMR will be recorded in preoperative hemograms Nodule sizes detected by preoperative Bethesda III cytology will be recorded The sizes of nodules with preoperative AUS cytology after thyroidectomy determined as a result of pathological examination will be recorded Patients with malignant cytology will be divided into papillary thyroid carcinoma PTC Follicular Thyroid Carcinoma FTC and tumor sizes will be recorded Among the patients included in the study BRAF molecular testing will be performed on the preoperative cytology of 25 patients whose thyroidectomy materials were reported to be malignant
The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology
Primary outcome Preoperative hemogram parameters Secondary outcome BRAF positivity This study aims to reduce unnecessary thyroidectomies thyroidectomy complications and treatment costs due to Bethesda 3 cytology
The age and gender of all patients to be included in the study will be recorded Mean Platelet Volume MPV Neutrophillymphocyte Ratio NLR PlateletLymphocyte Ratio PLR and LymphocyteMonocyte Ratio LMR will be recorded in preoperative hemograms Nodule sizes detected by preoperative Bethesda III cytology will be recorded The sizes of nodules with preoperative AUS cytology after thyroidectomy determined as a result of pathological examination will be recorded Patients with malignant cytology will be divided into papillary thyroid carcinoma PTC Follicular Thyroid Carcinoma FTC and tumor sizes will be recorded Among the patients included in the study BRAF molecular testing will be performed on the preoperative cytology of 25 patients whose thyroidectomy materials were reported to be malignant
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None